피부과용 OTC 의약품 : 세계 시장 점유율과 순위, 총판매량 및 수요 예측(2025-2031년)

The global market for Dermatology OTC Medications was estimated to be worth US$ 13630 million in 2024 and is forecast to a readjusted size of US$ 17050 million by 2031 with a CAGR of 3.3% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Dermatology OTC Medications cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Dermatology OTC (Over-the-Counter) medications refer to non-prescription drugs used to prevent, manage, or treat common skin conditions such as acne, eczema, dermatitis, fungal infections, dry skin, sunburn, and minor wounds. These products are widely available in pharmacies, supermarkets, and online, and include creams, ointments, gels, lotions, and medicated cleansers. They typically contain active ingredients like salicylic acid, benzoyl peroxide, hydrocortisone, antifungals, or antihistamines, and are designed for safe use without a doctor's prescription, offering convenient and cost-effective solutions for everyday dermatologic care.

Market competition is intense. Bayer, GSK, Teva, Johnson & Johnson, Novartis, Mylan, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers. Top 5 manufacturers accounted for 25.08% market share in 2019.

This report aims to provide a comprehensive presentation of the global market for Dermatology OTC Medications, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Dermatology OTC Medications by region & country, by Type, and by Application.

The Dermatology OTC Medications market size, estimations, and forecasts are provided in terms of sales volume (M Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dermatology OTC Medications.

Market Segmentation

By Company

• Bayer
• GSK
• Teva
• Johnson & Johnson
• Novartis
• Viatris
• Sun Pharmaceutical
• Aurobindo
• Galderma
• CR SANJIU
• Dr. Reddy's
• Lupin
• Bausch Health
• Cipla
• Qilu Pharmaceutical
• Almirall
• Lingrui
• Kaken Pharmaceutical
• Jingwei Pharma
• Zhiyuan Phamra

Segment by Type

• External Use
• Oral

Segment by Application

• Hospital
• Drug Store
• Other

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Dermatology OTC Medications manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Dermatology OTC Medications in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Dermatology OTC Medications in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Dermatology OTC Medications Product Introduction
• 1.2 Global Dermatology OTC Medications Market Size Forecast
  • 1.2.1 Global Dermatology OTC Medications Sales Value (2020-2031)
  • 1.2.2 Global Dermatology OTC Medications Sales Volume (2020-2031)
  • 1.2.3 Global Dermatology OTC Medications Sales Price (2020-2031)
• 1.3 Dermatology OTC Medications Market Trends & Drivers
  • 1.3.1 Dermatology OTC Medications Industry Trends
  • 1.3.2 Dermatology OTC Medications Market Drivers & Opportunity
  • 1.3.3 Dermatology OTC Medications Market Challenges
  • 1.3.4 Dermatology OTC Medications Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Dermatology OTC Medications Players Revenue Ranking (2024)
• 2.2 Global Dermatology OTC Medications Revenue by Company (2020-2025)
• 2.3 Global Dermatology OTC Medications Players Sales Volume Ranking (2024)
• 2.4 Global Dermatology OTC Medications Sales Volume by Company Players (2020-2025)
• 2.5 Global Dermatology OTC Medications Average Price by Company (2020-2025)
• 2.6 Key Manufacturers Dermatology OTC Medications Manufacturing Base and Headquarters
• 2.7 Key Manufacturers Dermatology OTC Medications Product Offered
• 2.8 Key Manufacturers Time to Begin Mass Production of Dermatology OTC Medications
• 2.9 Dermatology OTC Medications Market Competitive Analysis
  • 2.9.1 Dermatology OTC Medications Market Concentration Rate (2020-2025)
  • 2.9.2 Global 5 and 10 Largest Manufacturers by Dermatology OTC Medications Revenue in 2024
  • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dermatology OTC Medications as of 2024)
• 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 External Use
  • 3.1.2 Oral
• 3.2 Global Dermatology OTC Medications Sales Value by Type
  • 3.2.1 Global Dermatology OTC Medications Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Dermatology OTC Medications Sales Value, by Type (2020-2031)
  • 3.2.3 Global Dermatology OTC Medications Sales Value, by Type (%) (2020-2031)
• 3.3 Global Dermatology OTC Medications Sales Volume by Type
  • 3.3.1 Global Dermatology OTC Medications Sales Volume by Type (2020 VS 2024 VS 2031)
  • 3.3.2 Global Dermatology OTC Medications Sales Volume, by Type (2020-2031)
  • 3.3.3 Global Dermatology OTC Medications Sales Volume, by Type (%) (2020-2031)
• 3.4 Global Dermatology OTC Medications Average Price by Type (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Hospital
  • 4.1.2 Drug Store
  • 4.1.3 Other
• 4.2 Global Dermatology OTC Medications Sales Value by Application
  • 4.2.1 Global Dermatology OTC Medications Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Dermatology OTC Medications Sales Value, by Application (2020-2031)
  • 4.2.3 Global Dermatology OTC Medications Sales Value, by Application (%) (2020-2031)
• 4.3 Global Dermatology OTC Medications Sales Volume by Application
  • 4.3.1 Global Dermatology OTC Medications Sales Volume by Application (2020 VS 2024 VS 2031)
  • 4.3.2 Global Dermatology OTC Medications Sales Volume, by Application (2020-2031)
  • 4.3.3 Global Dermatology OTC Medications Sales Volume, by Application (%) (2020-2031)
• 4.4 Global Dermatology OTC Medications Average Price by Application (2020-2031)

5 Segmentation by Region

• 5.1 Global Dermatology OTC Medications Sales Value by Region
  • 5.1.1 Global Dermatology OTC Medications Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Dermatology OTC Medications Sales Value by Region (2020-2025)
  • 5.1.3 Global Dermatology OTC Medications Sales Value by Region (2026-2031)
  • 5.1.4 Global Dermatology OTC Medications Sales Value by Region (%), (2020-2031)
• 5.2 Global Dermatology OTC Medications Sales Volume by Region
  • 5.2.1 Global Dermatology OTC Medications Sales Volume by Region: 2020 VS 2024 VS 2031
  • 5.2.2 Global Dermatology OTC Medications Sales Volume by Region (2020-2025)
  • 5.2.3 Global Dermatology OTC Medications Sales Volume by Region (2026-2031)
  • 5.2.4 Global Dermatology OTC Medications Sales Volume by Region (%), (2020-2031)
• 5.3 Global Dermatology OTC Medications Average Price by Region (2020-2031)
• 5.4 North America
  • 5.4.1 North America Dermatology OTC Medications Sales Value, 2020-2031
  • 5.4.2 North America Dermatology OTC Medications Sales Value by Country (%), 2024 VS 2031
• 5.5 Europe
  • 5.5.1 Europe Dermatology OTC Medications Sales Value, 2020-2031
  • 5.5.2 Europe Dermatology OTC Medications Sales Value by Country (%), 2024 VS 2031
• 5.6 Asia Pacific
  • 5.6.1 Asia Pacific Dermatology OTC Medications Sales Value, 2020-2031
  • 5.6.2 Asia Pacific Dermatology OTC Medications Sales Value by Region (%), 2024 VS 2031
• 5.7 South America
  • 5.7.1 South America Dermatology OTC Medications Sales Value, 2020-2031
  • 5.7.2 South America Dermatology OTC Medications Sales Value by Country (%), 2024 VS 2031
• 5.8 Middle East & Africa
  • 5.8.1 Middle East & Africa Dermatology OTC Medications Sales Value, 2020-2031
  • 5.8.2 Middle East & Africa Dermatology OTC Medications Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Dermatology OTC Medications Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Dermatology OTC Medications Sales Value and Sales Volume
  • 6.2.1 Key Countries/Regions Dermatology OTC Medications Sales Value, 2020-2031
  • 6.2.2 Key Countries/Regions Dermatology OTC Medications Sales Volume, 2020-2031
• 6.3 United States
  • 6.3.1 United States Dermatology OTC Medications Sales Value, 2020-2031
  • 6.3.2 United States Dermatology OTC Medications Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Dermatology OTC Medications Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Dermatology OTC Medications Sales Value, 2020-2031
  • 6.4.2 Europe Dermatology OTC Medications Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Dermatology OTC Medications Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Dermatology OTC Medications Sales Value, 2020-2031
  • 6.5.2 China Dermatology OTC Medications Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Dermatology OTC Medications Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Dermatology OTC Medications Sales Value, 2020-2031
  • 6.6.2 Japan Dermatology OTC Medications Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Dermatology OTC Medications Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Dermatology OTC Medications Sales Value, 2020-2031
  • 6.7.2 South Korea Dermatology OTC Medications Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Dermatology OTC Medications Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Dermatology OTC Medications Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Dermatology OTC Medications Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Dermatology OTC Medications Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Dermatology OTC Medications Sales Value, 2020-2031
  • 6.9.2 India Dermatology OTC Medications Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Dermatology OTC Medications Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 Bayer
  • 7.1.1 Bayer Company Information
  • 7.1.2 Bayer Introduction and Business Overview
  • 7.1.3 Bayer Dermatology OTC Medications Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.1.4 Bayer Dermatology OTC Medications Product Offerings
  • 7.1.5 Bayer Recent Development
• 7.2 GSK
  • 7.2.1 GSK Company Information
  • 7.2.2 GSK Introduction and Business Overview
  • 7.2.3 GSK Dermatology OTC Medications Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.2.4 GSK Dermatology OTC Medications Product Offerings
  • 7.2.5 GSK Recent Development
• 7.3 Teva
  • 7.3.1 Teva Company Information
  • 7.3.2 Teva Introduction and Business Overview
  • 7.3.3 Teva Dermatology OTC Medications Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.3.4 Teva Dermatology OTC Medications Product Offerings
  • 7.3.5 Teva Recent Development
• 7.4 Johnson & Johnson
  • 7.4.1 Johnson & Johnson Company Information
  • 7.4.2 Johnson & Johnson Introduction and Business Overview
  • 7.4.3 Johnson & Johnson Dermatology OTC Medications Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.4.4 Johnson & Johnson Dermatology OTC Medications Product Offerings
  • 7.4.5 Johnson & Johnson Recent Development
• 7.5 Novartis
  • 7.5.1 Novartis Company Information
  • 7.5.2 Novartis Introduction and Business Overview
  • 7.5.3 Novartis Dermatology OTC Medications Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.5.4 Novartis Dermatology OTC Medications Product Offerings
  • 7.5.5 Novartis Recent Development
• 7.6 Viatris
  • 7.6.1 Viatris Company Information
  • 7.6.2 Viatris Introduction and Business Overview
  • 7.6.3 Viatris Dermatology OTC Medications Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.6.4 Viatris Dermatology OTC Medications Product Offerings
  • 7.6.5 Viatris Recent Development
• 7.7 Sun Pharmaceutical
  • 7.7.1 Sun Pharmaceutical Company Information
  • 7.7.2 Sun Pharmaceutical Introduction and Business Overview
  • 7.7.3 Sun Pharmaceutical Dermatology OTC Medications Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.7.4 Sun Pharmaceutical Dermatology OTC Medications Product Offerings
  • 7.7.5 Sun Pharmaceutical Recent Development
• 7.8 Aurobindo
  • 7.8.1 Aurobindo Company Information
  • 7.8.2 Aurobindo Introduction and Business Overview
  • 7.8.3 Aurobindo Dermatology OTC Medications Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.8.4 Aurobindo Dermatology OTC Medications Product Offerings
  • 7.8.5 Aurobindo Recent Development
• 7.9 Galderma
  • 7.9.1 Galderma Company Information
  • 7.9.2 Galderma Introduction and Business Overview
  • 7.9.3 Galderma Dermatology OTC Medications Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.9.4 Galderma Dermatology OTC Medications Product Offerings
  • 7.9.5 Galderma Recent Development
• 7.10 CR SANJIU
  • 7.10.1 CR SANJIU Company Information
  • 7.10.2 CR SANJIU Introduction and Business Overview
  • 7.10.3 CR SANJIU Dermatology OTC Medications Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.10.4 CR SANJIU Dermatology OTC Medications Product Offerings
  • 7.10.5 CR SANJIU Recent Development
• 7.11 Dr. Reddy's
  • 7.11.1 Dr. Reddy's Company Information
  • 7.11.2 Dr. Reddy's Introduction and Business Overview
  • 7.11.3 Dr. Reddy's Dermatology OTC Medications Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.11.4 Dr. Reddy's Dermatology OTC Medications Product Offerings
  • 7.11.5 Dr. Reddy's Recent Development
• 7.12 Lupin
  • 7.12.1 Lupin Company Information
  • 7.12.2 Lupin Introduction and Business Overview
  • 7.12.3 Lupin Dermatology OTC Medications Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.12.4 Lupin Dermatology OTC Medications Product Offerings
  • 7.12.5 Lupin Recent Development
• 7.13 Bausch Health
  • 7.13.1 Bausch Health Company Information
  • 7.13.2 Bausch Health Introduction and Business Overview
  • 7.13.3 Bausch Health Dermatology OTC Medications Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.13.4 Bausch Health Dermatology OTC Medications Product Offerings
  • 7.13.5 Bausch Health Recent Development
• 7.14 Cipla
  • 7.14.1 Cipla Company Information
  • 7.14.2 Cipla Introduction and Business Overview
  • 7.14.3 Cipla Dermatology OTC Medications Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.14.4 Cipla Dermatology OTC Medications Product Offerings
  • 7.14.5 Cipla Recent Development
• 7.15 Qilu Pharmaceutical
  • 7.15.1 Qilu Pharmaceutical Company Information
  • 7.15.2 Qilu Pharmaceutical Introduction and Business Overview
  • 7.15.3 Qilu Pharmaceutical Dermatology OTC Medications Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.15.4 Qilu Pharmaceutical Dermatology OTC Medications Product Offerings
  • 7.15.5 Qilu Pharmaceutical Recent Development
• 7.16 Almirall
  • 7.16.1 Almirall Company Information
  • 7.16.2 Almirall Introduction and Business Overview
  • 7.16.3 Almirall Dermatology OTC Medications Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.16.4 Almirall Dermatology OTC Medications Product Offerings
  • 7.16.5 Almirall Recent Development
• 7.17 Lingrui
  • 7.17.1 Lingrui Company Information
  • 7.17.2 Lingrui Introduction and Business Overview
  • 7.17.3 Lingrui Dermatology OTC Medications Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.17.4 Lingrui Dermatology OTC Medications Product Offerings
  • 7.17.5 Lingrui Recent Development
• 7.18 Kaken Pharmaceutical
  • 7.18.1 Kaken Pharmaceutical Company Information
  • 7.18.2 Kaken Pharmaceutical Introduction and Business Overview
  • 7.18.3 Kaken Pharmaceutical Dermatology OTC Medications Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.18.4 Kaken Pharmaceutical Dermatology OTC Medications Product Offerings
  • 7.18.5 Kaken Pharmaceutical Recent Development
• 7.19 Jingwei Pharma
  • 7.19.1 Jingwei Pharma Company Information
  • 7.19.2 Jingwei Pharma Introduction and Business Overview
  • 7.19.3 Jingwei Pharma Dermatology OTC Medications Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.19.4 Jingwei Pharma Dermatology OTC Medications Product Offerings
  • 7.19.5 Jingwei Pharma Recent Development
• 7.20 Zhiyuan Phamra
  • 7.20.1 Zhiyuan Phamra Company Information
  • 7.20.2 Zhiyuan Phamra Introduction and Business Overview
  • 7.20.3 Zhiyuan Phamra Dermatology OTC Medications Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.20.4 Zhiyuan Phamra Dermatology OTC Medications Product Offerings
  • 7.20.5 Zhiyuan Phamra Recent Development

8 Industry Chain Analysis

• 8.1 Dermatology OTC Medications Industrial Chain
• 8.2 Dermatology OTC Medications Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Dermatology OTC Medications Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Dermatology OTC Medications Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer